Reported relationships
Latest disclosed role at each company.
| Company | Last reported as | Report date | Published |
|---|---|---|---|
| ABBOTT LABORATORIESABT · Entity 2314 | Senior Vice President | December 31, 2018 | January 03, 2019 |
Disclosed balances
About these balances
Latest available filing per company, not a reconstructed current portfolio. Matching sequences show the last reported balance with all source rows expandable; grouping alone does not establish account ownership. Do not add unresolved positions together. Filings may omit unchanged positions, and amendments may correct only part of an older disclosure. Jointly reported shares are not necessarily this owner's personal holdings.
ABBOTT LABORATORIES
Report date December 31, 2018 · Filed January 03, 2019
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Common shares without par valueSEC Table I · non-derivative | Direct | 16,165 |
Reported balance
After 2018-12-31 transaction · row 1
1 source rowRow 1 · 2018-12-31 · Tax withholding · Disposed 481 · Balance 16,165 |
Transaction history
JSON APIPurchases/sales include open-market and private transactions. Plan disclosure applies to the filing; individual rows may differ. “Not disclosed” is not “unplanned.”
The cutoff filters transaction history only. Company summaries and owner relationships show the latest available disclosures. Parser corrections can improve historical records.
| Transaction date | Company | Activity / security | Shares / units | Reported price | Reported value | Details |
|---|---|---|---|---|---|---|
| December 31, 2018 Filed Jan 3, 2019 22:22 UTC | ABBOTT LABORATORIES ABT · Entity 2314 | Tax withholdingCommon shares without par value | 481 | $71.09 | $34,194.29 |
DisclosureSEC source: 0001179110-19-000289 · edgar.xml · nonDerivative · entry 1 Shrimpton Sean · CIK 0001706711 · Senior Vice President 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 16,165 Read SEC document |
| May 15, 2018 Filed May 16, 2018 21:08 UTC | ABBOTT LABORATORIES ABT · Entity 2314 | Tax withholdingCommon shares without par value | 811 | $62.02 | $50,298.22 |
DisclosureSEC source: 0001179110-18-006899 · edgar.xml · nonDerivative · entry 2 Shrimpton Sean · CIK 0001706711 · Senior Vice President 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 16,646 Read SEC document |
| May 15, 2018 Filed May 16, 2018 21:08 UTC | ABBOTT LABORATORIES ABT · Entity 2314 | GrantCommon shares without par value | 1,801 | $0.00 | $0.00 |
DisclosureSEC source: 0001179110-18-006899 · edgar.xml · nonDerivative · entry 1 Shrimpton Sean · CIK 0001706711 · Senior Vice President 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 17,457 F1 · shares: Settlement of performance-based restricted stock units in shares in a transaction exempt from Section 16(b) under Rule 16b-3. Read SEC document |
| February 19, 2018 Filed Feb 21, 2018 23:22 UTC | ABBOTT LABORATORIES ABT · Entity 2314 | Tax withholdingCommon shares without par value | 1,075 | $60.17 | $64,682.75 |
DisclosureSEC source: 0001179110-18-002516 · edgar.xml · nonDerivative · entry 2 Shrimpton Sean · CIK 0001706711 · Senior Vice President 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 15,656 Read SEC document |
| February 17, 2018 Filed Feb 21, 2018 23:22 UTC | ABBOTT LABORATORIES ABT · Entity 2314 | Tax withholdingCommon shares without par value | 1,423 | $60.17 | $85,621.91 |
DisclosureSEC source: 0001179110-18-002516 · edgar.xml · nonDerivative · entry 1 Shrimpton Sean · CIK 0001706711 · Senior Vice President 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 16,731 Read SEC document |
| February 16, 2018 Filed Feb 21, 2018 23:22 UTC | ABBOTT LABORATORIES ABT · Entity 2314 | GrantOption (right to buy) · Derivative | 110,146 | $0.00 Strike: $59.94 | $0.00 |
DisclosureSEC source: 0001179110-18-002516 · edgar.xml · derivative · entry 3 Shrimpton Sean · CIK 0001706711 · Senior Vice President 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 110,146 Underlying: Common shares · 110,146 shares Expires 2028-02-15 F1 · security: Employee stock option granted pursuant to the Abbott Laboratories 2017 Incentive Stock Program in a transaction exempt from Section 16 under Rule 16b-3. The option becomes exercisable in annual increments of 36,716 on 02/16/2019, 36,715 on 02/16/2020, and 36,715 on 02/16/2021. Read SEC document |
| December 31, 2017 Filed Jan 3, 2018 22:16 UTC | ABBOTT LABORATORIES ABT · Entity 2314 | Tax withholdingCommon shares without par value | 502 | $57.07 | $28,649.14 |
DisclosureSEC source: 0001179110-18-000342 · edgar.xml · nonDerivative · entry 1 Shrimpton Sean · CIK 0001706711 · Senior Vice President 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 18,154 Read SEC document |
| May 15, 2017 Filed May 17, 2017 21:06 UTC | ABBOTT LABORATORIES ABT · Entity 2314 | GrantOption (right to buy) · Derivative | 92,032 | $0.00 Strike: $44.08 | $0.00 |
DisclosureSEC source: 0001179110-17-007429 · edgar.xml · derivative · entry 1 Shrimpton Sean · CIK 0001706711 · Senior Vice President 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 92,032 Underlying: Common shares · 92,032 shares Expires 2027-05-14 F1 · security: Employee stock option granted pursuant to the Abbott Laboratories 2017 Incentive Stock Program in a transaction exempt from Section 16 under Rule 16b-3. The option becomes exercisable in annual increments of 30,678 on 5/15/2018, 30,677 on 5/15/2019, and 30,677 on 5/15/2020. Read SEC document |
Value uses the disclosed total when available, otherwise shares × reported transaction price. It is not an estimate of exercise cash cost or investment performance.